Market Size & Forecast

The Toxoplasmosis Testing Market was valued at approximately US$354 million in 2019 and is anticipated to reach US$577 million by 2027, growing at a CAGR of 6.4% between 2022 and 2029.

Serological tests remain dominant, projected to climb from US$ $260 million in 2019 to US$ $427 million by 2027 at a CAGR of 6.5%, while diagnostic labs lead the end-user segment with nearly 50% market share.

Introduction & Definition

Toxoplasmosis testing encompasses diagnostic methods—serological assays, PCR-based molecular tests, and imaging for congenital cases—targeting Toxoplasma gondii, a common parasite. Testing is critical for pregnant women, immunocompromised patients, and in food safety screening, helping detect acute infections or past exposure via IgG/IgM serology, though PCR delivers early diagnosis and higher sensitivity.

Segmentation Analysis

• By Test Type:
  

  • Serological tests dominate globally, offering high throughputs and cost-efficiency.
    

  • PCR & molecular diagnostics are the fastest growing (~8.1% CAGR through 2027), offering precise detection even in early or ocular toxoplasmosis.
    

  • Imaging (ultrasound/MRI) and invasive techniques (amniocentesis, biopsy) are important for prenatal and cerebral toxo cases.
    

• By End User:
  

  • Hospitals lead due to infrastructure and patient inflow.
    

  • Diagnostic laboratories are scaling cost-effective PCR and multiplex assays.
    

  • Clinics and specialized maternity centers are increasingly adopting point-of-care kits.

Geographical Insights

• North America accounted for over 35% of the market in 2019 and is expected to grow due to high pork consumption, diagnostic awareness, and advanced healthcare.
  

• Europe shows higher seroprevalence (20–77%), prompting strong demand for routine testing, especially in Germany and France.
  

• Asia-Pacific is expanding with investments in diagnostic infrastructure and increasing foodborne risk, led by China, India, and Japan.
  

• Japan reports around 10.3% antibody prevalence among pregnant women, especially those aged 35+, with growing prenatal screening programs.

Latest News & Industry Trends (US & Japan)

United States:

• Rapid adoption of multiplex PCR panels and automated immunoassays has improved turnaround times, with real-time PCR now providing results within hours.
  

• Point-of-care Rapid tests are being piloted, especially in prenatal and primary care settings, to enable early intervention.

Japan:

• Integration of automated PCR platforms in perinatal clinics supports early detection of congenital toxoplasmosis.
  

• Increased government focus on food safety testing, due to widespread consumption of undercooked or free-range meats, is driving demand for lab testing.

  To get the free sample, click on https://www.datamintelligence.com/download-sample/toxoplasmosis-testing-market

Competitive Landscape

Key players in the market include

• ACON Laboratories offers EIA kits for prenatal IgG screening
  

• Abbott
  

• BioMérieux
  

• Bio-Rad Laboratories
  

• DiaSorin
  

• Thermo Fisher Scientific
  

• Biokit
  

• Genemedi
  

• Gold Standard Diagnostics
  

These companies are focusing on strategies like new product launches, acquisitions, automated multiplex assay development, and expansion into the point-of-care segment.

Impact Analysis

• Improved public health outcomes: Early detection in pregnancy significantly reduces congenital toxoplasmosis risks.
  

• Clinical efficiency: Rapid molecular diagnostics cut result times dramatically, increasing access in underserved regions.
  

• Economic efficiency: Automated and multiplex testing lowers per-test costs, enabling wider routine screening.
  

• Global equity: Point-of-care and telemedicine-based testing improve access in low-resource settings.

Key Developments

• Bio-Rad acquired Curiosity Diagnostics to enhance its molecular diagnostics portfolio.
  

• Rapid multiplex PCR assays and automated testing platforms have been rolled out across North America and Europe.
  

• Pilot programs in the US and Japan have launched rapid IgG/IgM point-of-care kits and bundled prenatal testing initiatives. About Us

DataM Intelligence is a global market intelligence firm dedicated to providing actionable insights and data-driven strategies. Our expert research teams serve a wide range of industries, including healthcare, biotechnology, technology, and chemicals, helping clients make well-informed decisions.

Contact Us

DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877‑441‑4866